77 completed, 12 active not recruiting, 5 terminated, 5 withdrawn. 64 Phase 1, 41 Phase 2, 6 Phase 3, 1 Not applicable.
Follow veliparib: new trials by email Literature Review of veliparib trials Research Report on veliparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer Veliparib, capsule, Veliparib, tablet, Carboplatin - Cancer - Ovarian | Phase 1 | Withdrawn | AbbVie | 2021-11-15 | 2021-12-08 | |
| Arterial Hypertension Related to PARP Inhibitors (ArteRIB) olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib - Cancer | Completed | University Hospital, Caen | 2336 | 2021-02-24 | 2023-06-06 | |
| Pancytopenia Related to PARP Inhibitors (PancytoRIB) PARP inhibitor - Cancer | Completed | University Hospital, Caen | 200 | 2021-02-07 | 2021-09-23 | |
| Response to PARP Inhibitor Predicted by the RAD51 Assay Veliparib - Cancer | Phase 2 | Withdrawn | University Medical Center Groningen | 2019-11-01 | 2024-05-03 | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Radiation Therapy, Temozolomide, Veliparib - Anaplastic Astrocytoma, Glioblastoma | Phase 2 | Active not recruiting | Children's Oncology Group | 38 | 2018-11-06 | 2026-10-06 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Carboplatin, Topotecan, Topotecan Hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2018-09-24 | 2026-06-23 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Carboplatin, Eribulin, Veliparib - Breast Cancer Stage IV, Ovarian Cancer | Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2017-09-30 | 2017-10-10 | |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors Veliparib + VX-970 + Cisplatin - Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 53 | 2017-08-09 | 2022-02-08 |
| Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis - Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2017-05-31 | 2025-02-10 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study - Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma | Phase 1 | Completed | Northwestern University | 15 | 2017-05-23 | 2024-06-12 |
| Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy - Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 363 | 2017-01-11 | 2025-12-04 |
| Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) pemetrexed, nivolumab, paclitaxel - Non-Small Cell Lung Cancer | Phase 1 | Completed | AbbVie | 25 | 2016-12-23 | 2019-10-23 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 123 | 2016-10-27 | 2026-05-20 |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan veliparib, Topotecan - Small Cell Lung Cancer SCLC | Phase 1 | Unknown | Central European Society for Anticancer Drug Research | 30 | 2016-10-01 | 2021-01-27 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Cisplatin, Laboratory Biomarker Analysis, Placebo Administration - Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 344 | 2016-09-15 | 2026-04-08 |
| Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer Veliparib, Gemcitabine, Carboplatin - Testicular Cancer | Phase 2 | Completed | National Cancer Institute, Slovakia | 15 | 2016-08-01 | 2021-03-03 |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Veliparib, Paclitaxel, Carboplatin - Ovarian Cancer, Ovarian Neoplasm | Phase 3 | Terminated | AbbVie | 1140 | 2015-07-14 | 2024-10-26 |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer veliparib, carboplatin, paclitaxel - Ovarian Cancer | Phase 1 | Completed | AbbVie | 9 | 2015-07-01 | 2017-11-20 |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) Paclitaxel, Placebo for Veliparib, Carboplatin - Non-small Cell Lung Cancer Stage III | Phase 1 / Phase 2 | Terminated | AbbVie | 48 | 2015-04-30 | 2020-07-22 |
Showing 20 of 103. Sign in to see all of them.
Breast Neoplasms (23) · Ovarian Neoplasms (20) · Triple Negative Breast Neoplasms (14) · Neoplasms (11) · Fallopian Tube Neoplasms (9) · Neoplasm Metastasis (9) · Carcinoma, Non-Small-Cell Lung (7) · Pancreatic Neoplasms (7) · Astrocytoma (5) · Glioblastoma (5) · Brain Neoplasms (4) · Colonic Neoplasms (4) · Gliosarcoma (4) · Small Cell Lung Carcinoma (4) · Stomach Neoplasms (4)
National Cancer Institute (NCI) (47) · AbbVie (19) · AbbVie (prior sponsor, Abbott) (10) · Georgetown University (3) · University Hospital, Caen (2) · University of Washington (2) · Vejle Hospital (2) · Abbott (1) · Cedars-Sinai Medical Center (1) · Central European Society for Anticancer Drug Research (1) · Children's Oncology Group (1) · National Cancer Institute, Slovakia (1) · National Institutes of Health Clinical Center (CC) (1) · Northwestern University (1) · QuantumLeap Healthcare Collaborative (1)
United States (80) · Canada (13) · Australia (10) · Spain (9) · Netherlands (8) · Denmark (7) · France (7) · Hungary (7) · Israel (7) · Puerto Rico (7) · Czechia (6) · Russia (6) · South Korea (6) · United Kingdom (6) · Germany (5)
Bhardwaj Desai, MD (3) · Hideyuki Hashiba, BS (3) · Andrea E Wahner Hendrickson (2) · Keith W Pratz (2) · Mark D McKee, MD (2) · Philip Komarnitsky, MD (2) · Shannon Puhalla (2) · Stacie Shepherd, PhD (2) · Vincent Giranda, MD (2) · A P Chen (1) · Aiwu R He, MD PhD (1) · Alice Chen, M.D. (1)
PMID 28665051, PMID 19364967, PMID 21795476, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 24764124, PMID 25053388, PMID 25589624, PMID 25682091, PMID 26202595, PMID 26433581, PMID 26449224, PMID 26602013, PMID 26615020, PMID 27406346, PMID 27406347, PMID 27655223, PMID 27709282, PMID 27739325, PMID 27803064, PMID 27998970, PMID 28243955, PMID 28314788, PMID 28497258, PMID 28497757, PMID 28837250, PMID 28851423, PMID 29223478, PMID 29261439, PMID 29501363, PMID 29558281, PMID 29579325, PMID 29733524, PMID 29906251, PMID 30104007, PMID 30327308, PMID 30523756, PMID 31606288, PMID 31708167, PMID 31913413, PMID 32009149, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 32860331, PMID 32861273, PMID 33084020
UM1CA186691 (8), U01CA070095 (6), U01CA099168 (6), 2014 (5), P30CA047904 (5), U10CA027469 (5), U10CA180868 (5), N01CM00071 (4), UM1CA186716 (4), N01CM00038 (3), N01CM00039 (3), N01CM62201 (3), N01CM62209 (3), P30CA006973 (3), P30CA008748 (3)